Harmony Biosciences Holdings (HRMY) Share-based Compensation (2019 - 2026)

Harmony Biosciences Holdings has disclosed Share-based Compensation across 8 years of filings, most recently posting $10.6 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $10.6 million, down 15.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $43.0 million (down 4.37% YoY), and the FY2025 annual result was $44.9 million, up 5.38% from the prior year.
• Share-based Compensation came in at $10.6 million for Q1 2026 at Harmony Biosciences Holdings, up from $10.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $12.5 million in Q1 2025 to a low of $4.6 million in Q1 2022.
• The 5-year median for Share-based Compensation is $10.0 million (2025), against an average of $9.2 million.
• Across the five-year window, Share-based Compensation jumped 93.62% in 2022 and fell 15.03% in 2026, its largest moves.
• Harmony Biosciences Holdings' Share-based Compensation stood at $6.9 million in 2022, then surged by 35.38% to $9.4 million in 2023, then rose by 7.22% to $10.1 million in 2024, then dropped by 0.99% to $10.0 million in 2025, then rose by 6.5% to $10.6 million in 2026.
• The last three Share-based Compensation figures came in at $10.6 million (Q1 2026), $10.0 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.